Figure 1

Kaplan–Meier analysis of progression-free survival (PFS) and overall survival (OS). PFS is shown in A, C, E, and G. OS is shown in B, D, F, and H. PFS and OS were examined based on rilotumumab dose (A, B), rilotumumab exposure (C, D), rilotumumab exposure in the MET-positive subgroup (E, F), and rilotumumab exposure in the MET-negative subgroup (G, H). Low rilotumumab exposure was defined as C_minss<94 μg ml⁻¹, and high rilotumumab exposure was defined as C_minss⩾94 μg ml⁻¹. MET positivity was defined as ⩾25% membranous staining of tumour cells at any intensity, and MET negativity was defined as <25% membranous staining. CI, confidence interval.